Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.  2019.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.. BMC Neurol. 19(1):116.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.

Bourre B, Gueudry J, Lefaucheur R, Borden A, Maltête D, Patel SS, Van Tassel SHaseltine, Gupta MP, Orlin A, Nealon NM.  2016.  Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.. Neurology. 86(3):312-3.